Core--Protocol Specific Research Support

协议特定研究支持（PSRS）是扩大KCI研究者发起的临床试验数量的一项努力。必须支持进行初步研究，其中大部分研究目前没有得到NCI或其他机构的资助。PSRS的目的是提供一种管理支持机制，以提供数据管理、患者数据收集，并支持癌症中心内的创新临床试验。目标是促进研究者发起的试验，将基础科学实验室的新结果带到临床和人口研究领域。授予研究者PSRS是在科学领导委员会的建议下完成的。中心副主任、项目负责人或多学科团队负责人可以提名支持方案。提案将根据其科学价值和在癌症中心内开发新研究途径的重要性进行评估。虽然所有建议都得到认真考虑，但鼓励那些显示有可能发展新的研究途径和获得外部资金的研究。在癌症中心有许多研究者发起的转化研究。这些包括新的分子靶向治疗和功能成像技术。这些试验试图测试新的靶向疗法，既可以作为单一药物，

The Protocol-Specific Research Support (PSRS) is an effort to expand the number of investigator-initiated clinical trials at KCI. Support must be available to conduct preliminary studies, most of which are not presently funded by the NCI or other agencies. The purpose of the PSRS is to provide an administrative support mechanism to provide data management, collection of patient data, and to support innovative clinical trials within the Cancer Center. The objective is to foster investigator-initiated trials, which bring new results from our basic science laboratories to the clinical and population studies arenas. The awarding of PSRS to an investigator is done at the recommendation of the Scientific Leadersip Council. Associate center directors, Program leaders, or heads of the Multidisciplinary Teams can nominate protocols for support. Proposals are evaluated for their scientific merit and importance in developing new avenues of research within the Cancer Center. Although all proposals are given serious consideration, studies that show the potential to develop new avenues of research and secure external funding are encouraged. There are many investigator-initiated translational studies within the Cancer Center. These include novel and molecular targeted therapies, and functioning imaging techniques. These trials seek to test new, targeted therapies both as single agents, and in combination with more established cytotoxic therapy. They often include measurements of treatment effect based on blood samples and tumor biopsies. New imaging approaches are integral to this work as they provide a noninvasive way to test these treatment approaches. For the future, we plan to support a mixture of Phase I, Phase II, and imaging/correlative trials. Funding support for 1.5 FTE data management to support the innovative trials is requested. Data management will include confirming patient eligibility prior to registration to the trial, abstracting and collating data from various sources ensuring that qualtiy control checks are being conducted.